The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein

Seminars in Cancer Biology

Volumn 7, Issue 2, 1996, Pages 79-86

  King, C Richter ^a   Fischer, Paul H ^b   Rando, Robert F ^c   Pastan, Ira ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b GENVEC INC   (United States)

^c Antigenics Inc   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

erbB 2; neu; Oncoprotein; Preclinical; Therapy

Indexed keywords

IMMUNOTOXIN; ONCOPROTEIN; RECOMBINANT PROTEIN;

ANTIBODY COMBINING SITE; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; IMMUNE RESPONSE; LIVER TOXICITY; NONHUMAN; ONCOGENE NEU; REVIEW;

EID: 0029870563     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1996.0012     Document Type: Review

References (48)

1. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
3. Semba K, Kamata N, Toyoshima K, Yamamoto T (1985) A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497-6501
4. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987) erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182
5. Hudziak RM, Schlessinger J, Ullrich A (1987) Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159-7163
6. Ciardiello F, Gottardis M, Basolo F, Pepe S, Normanno N, Dickson RB, Bianco AR, Salomon DS (1992) Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. Mol Carcinog 6:43-52
7. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1993) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast. Cancer Res Treat 24:85-95
8. Kraus MH, Popescu NC, Amsbaugh SC, King CR (1987) Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6:605-610
9. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE (1988) Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243
10. Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953-962
11. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
12. Rubin SC, Finstad CL, Federici MG, Scheiner L, Lloyd KO, Hoskins WJ (1994) Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 73:1456-1459
13. Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H, Cline MJ (1986) Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1:765-767
14. Falck VG, Gullick WJ (1989) c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. J Pathol 159:107-111
15. Zhau HE, Zhang X, von Eschenbach AC, Scorsone K, Babaian RJ, Ro JY, Hung MC (1990) Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog 3:254-257
16. Lee SE, Chow NH, Chi YC, Tzai TS, Yang WH, Lin SN (1994) Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res 14:1317-1324
17. Lipponen P (1993) Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer 29A:749-753
18. Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D, Schwartz DA (1994) C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93:516-520
19. Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK, Hung MC (1995) Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst 87:682-684
20. Volm M, Drings P, Wodrich W, van Kaick G (1993) Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases. Clin Exp Metastasis 11:325-329
21. Kern JA, Robinson RA, Gazdar A, Torney L, Weiner DB (1992) Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines. Am J Resp Cell Mol Biol 6:359-363
22. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112
23. Niehans GA, Singleton TP, Dykoski D, Kiang DT (1993) Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85:1230-1235
24. Park JW, Stagg R, Lewis GD, Carter P, Maneval D, Slamon DJ, Jaffe H, Shepard HM (1992) Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treat Res 61:193-211
25. Kasprzyk PG, Song SU, Di Fiore PP, King CR (1992) Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52:2771-2776
26. Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE (1993) Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 68:1140-1145
27. Drebin JA, Link VC, Weinberg RA, Greene MI (1986) Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Nayl Acad Sci USA 83:9129-9133
28. Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB, Ullrich A, Sela M, Yarden Y (1992) Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res 52:2580-2589
29. Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB, Alpaugh RK (1993) Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol 151:2877-2886
30. Weiner LM, Holmes M, Adams GP, La Creta F, Watts P, Garcia de Palazzo I (1993) A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53:94-100
31. Carter P, Rodrigues ML, Lewis GD, Figari I, Shalaby MR (1994) Towards an immunotherapy for p185HER2 overexpressing tumors. Adv Exp Med Biol 353:83-94
32. Lyall RM, Zilberstein A, Gazit A, Gilon C, Levitzki A, Schlessinger J (1989) Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J Biol Chem 264:14503-14509
33. Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782-1788
34. Fischer PH, Bird RE, Kasprzyk PG, King CR, Turner NA, Pastan I, Kihara A, Batra J (1994) In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein. Adv Enzyme Reg 34:119-128
35. Bast RC, Jr, Xu F, Yu Y, Crews J, Argon Y, Maier L, Lidor Y, Berchuck A, Boyer CM (1994) Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer. Immunol Ser 61:23-30
36. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR (1992) Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 89:5867-5871
37. Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B, Pastan I (1994) Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 33:5451-5459
38. Brinkmann U, Pastan I (1994) Immunotoxins against cancer. Biochim Biophys Acta 1198:27-45
39. Fitzgerald D, Pastan I (1993) Pseudomonas exotoxin and recombinant immunotoxins derived from it. Ann NY Acad Sci 685:740-745
40. Reiter Y, Brinkmann U, Jung SH, Lee B, Kasprzyk PG, King CR, Pastan I (1994) Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem 269:18327-18331
41. Reiter Y, Kreitman RJ, Brinkmann U, Pastan I (1994) Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int J Cancer 58:142-149
42. Reiter Y, Pai LH, Brinkmann U, Wang QC, Pastan I (1994) Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res 54:2714-2718
43. Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE (1992) Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 52:6310-6317
44. Kasprzyk PG, Sullivan TL, Hunt JD, Gubish CT, Scoppa CA, Oelkuct M, Bird RE, Fischer PH, Siegfried JM, King CR (1996) Activity of an anti-erbB-2 recombinant toxin, OLX-209, on lung cancer cell lines in the absence of erbB-2 gene amplification. Clin Cancer Res 2:75-80
45. Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271:58-65
46. Boucher Y, Jain RK (1992) Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52:5110-5114
47. Tepler I, Schwartz G, Parker K, Charette J, Kadin ME, Woodworth TG, Schnipper LE (1994) Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 73:1276-1285
48. Le Maistre CF, Craig FE, Meneghetti C, McMullin B, Parker K, Reuben J, Boldt DH, Rosenblum M, Woodworth T (1993) Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res 53:3930-3934